DE69905488T2 - Prostaglandin-konjugate zur behandlung von knochenkrankheiten - Google Patents
Prostaglandin-konjugate zur behandlung von knochenkrankheitenInfo
- Publication number
- DE69905488T2 DE69905488T2 DE69905488T DE69905488T DE69905488T2 DE 69905488 T2 DE69905488 T2 DE 69905488T2 DE 69905488 T DE69905488 T DE 69905488T DE 69905488 T DE69905488 T DE 69905488T DE 69905488 T2 DE69905488 T2 DE 69905488T2
- Authority
- DE
- Germany
- Prior art keywords
- conjugates
- prostaglandin
- bone diseases
- treating bone
- prostaglandin conjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000020084 Bone disease Diseases 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- 229940122361 Bisphosphonate Drugs 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3869—Polyphosphonic acids containing carboxylic acid or carboxylic acid derivative substituents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3865—Polyphosphonic acids containing sulfur substituents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10930798P | 1998-11-20 | 1998-11-20 | |
PCT/CA1999/001111 WO2000031084A1 (en) | 1998-11-20 | 1999-11-18 | Prostaglandin conjugates for treating or preventing bone disease |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69905488D1 DE69905488D1 (de) | 2003-03-27 |
DE69905488T2 true DE69905488T2 (de) | 2003-12-24 |
Family
ID=22326974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69905488T Expired - Fee Related DE69905488T2 (de) | 1998-11-20 | 1999-11-18 | Prostaglandin-konjugate zur behandlung von knochenkrankheiten |
Country Status (9)
Country | Link |
---|---|
US (1) | US6121253A (de) |
EP (1) | EP1131327B1 (de) |
JP (1) | JP2002530411A (de) |
AT (1) | ATE232874T1 (de) |
AU (1) | AU762396B2 (de) |
CA (1) | CA2351679A1 (de) |
DE (1) | DE69905488T2 (de) |
ES (1) | ES2191475T3 (de) |
WO (1) | WO2000031084A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6896871B2 (en) | 1998-04-02 | 2005-05-24 | Mbc Research, Inc. | Biphosphonate conjugates and methods of making and using the same |
US7598246B2 (en) * | 1998-04-02 | 2009-10-06 | Mbc Pharma, Inc. | Bisphosphonate conjugates and methods of making and using the same |
US8586781B2 (en) | 1998-04-02 | 2013-11-19 | Mbc Pharma, Inc. | Bone targeted therapeutics and methods of making and using the same |
KR100593393B1 (ko) | 1999-01-20 | 2006-06-28 | 다카라 바이오 가부시키가이샤 | 치료제 |
ES2232434T3 (es) | 1999-03-05 | 2005-06-01 | Duke University | Analogos de prostaglandinas c-16 fp selectivas insaturadas. |
ATE243215T1 (de) * | 1999-08-04 | 2003-07-15 | Procter & Gamble | Neue 2-decarboxy-2-phosphinico prostaglandin f analoge |
AU2001236454A1 (en) * | 2000-01-12 | 2001-07-24 | Emory University | Use of cyclopentenone derivatives for bone and periodontal regeneration |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
US6476006B2 (en) * | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
EP2260852A3 (de) * | 2001-04-10 | 2011-01-12 | MBC Pharma, Inc. | Konjugate aus Bisphosphonaten und Methoden zu deren Herstellung und Anwendung |
AU2003231255A1 (en) * | 2002-05-02 | 2003-12-31 | Osteoscreen, Inc. | Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate) |
EP1723132A1 (de) | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Agonisten des ep2-rezeptors |
JP2009505973A (ja) | 2005-08-09 | 2009-02-12 | アステランド ユーケイ リミテッド | Ep2受容体アゴニスト |
BRPI0707516A2 (pt) * | 2006-02-06 | 2011-05-10 | Cypress Bioscience Inc | composiÇÕes que compreendem um bisfosfonato e um antifolato |
US20100099640A1 (en) * | 2007-05-04 | 2010-04-22 | Joannes Geuns | Tissue degeneration protection |
EP2220057A4 (de) | 2007-11-14 | 2011-10-12 | Cayman Chem Co | Prostaglandin-e1- und e2-analoga zur behandlung verschiedener medizinischer leiden |
US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
CA2738045C (en) * | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
CA2843885C (en) | 2011-08-01 | 2020-03-10 | Mbc Pharma, Inc. | Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
CA2988523A1 (en) | 2015-06-12 | 2016-12-15 | Simon Fraser University | Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof |
US11793452B2 (en) | 2019-10-03 | 2023-10-24 | Johnson & Johnson Consumer Inc. | Method of visualizing and quantifying remineralization |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3975404A (en) * | 1971-05-04 | 1976-08-17 | The Upjohn Company | Bicyclic lactone intermediates |
US3927197A (en) * | 1974-04-19 | 1975-12-16 | Pfizer | Tertiary alcohol stabilized E-series prostaglandins |
US4018892A (en) * | 1975-08-06 | 1977-04-19 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4097601A (en) * | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
US4171331A (en) * | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
ATE114473T1 (de) * | 1984-04-30 | 1994-12-15 | Procter & Gamble | Ausrüstung für die verwendung bei der behandlung von osteoporose. |
JPS6191137A (ja) * | 1984-10-11 | 1986-05-09 | Kao Corp | 外用薬剤組成物 |
DE3519361A1 (de) * | 1985-05-30 | 1986-12-04 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen |
US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
US5071840A (en) * | 1986-12-19 | 1991-12-10 | Norwich Eaton Pharmaceuticals, Inc. | Certain heterocyclic substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism |
EP0341961A3 (de) * | 1988-05-09 | 1990-06-20 | Merck & Co. Inc. | Polymalonsäuren als Knochenaffinitätsagent |
JPH0778024B2 (ja) * | 1988-10-14 | 1995-08-23 | 藤沢薬品工業株式会社 | 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤 |
JPH0759505B2 (ja) * | 1988-11-17 | 1995-06-28 | 帝人株式会社 | シクロペンテノン類を活性成分とする骨形成促進剤 |
US5071655A (en) * | 1990-01-12 | 1991-12-10 | Baylink David J | Pharmaceutical combination for treatment of bone-wasting diseases |
EP0496520A1 (de) * | 1991-01-22 | 1992-07-29 | Merck & Co. Inc. | Knochenaktive Verbindungen |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
DK0642519T3 (da) * | 1992-05-29 | 2000-09-18 | Procter & Gamble Pharma | Svovlholdige phosphonatforbindelser til behandling af unormal calcium- og phosphatmetabolisme |
US5409911A (en) * | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
-
1999
- 1999-11-15 US US09/440,351 patent/US6121253A/en not_active Expired - Fee Related
- 1999-11-18 DE DE69905488T patent/DE69905488T2/de not_active Expired - Fee Related
- 1999-11-18 ES ES99955618T patent/ES2191475T3/es not_active Expired - Lifetime
- 1999-11-18 AU AU12556/00A patent/AU762396B2/en not_active Ceased
- 1999-11-18 CA CA002351679A patent/CA2351679A1/en not_active Abandoned
- 1999-11-18 WO PCT/CA1999/001111 patent/WO2000031084A1/en active IP Right Grant
- 1999-11-18 JP JP2000583912A patent/JP2002530411A/ja active Pending
- 1999-11-18 EP EP99955618A patent/EP1131327B1/de not_active Expired - Lifetime
- 1999-11-18 AT AT99955618T patent/ATE232874T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69905488D1 (de) | 2003-03-27 |
ES2191475T3 (es) | 2003-09-01 |
ATE232874T1 (de) | 2003-03-15 |
EP1131327A1 (de) | 2001-09-12 |
AU762396B2 (en) | 2003-06-26 |
CA2351679A1 (en) | 2000-06-02 |
WO2000031084A1 (en) | 2000-06-02 |
EP1131327B1 (de) | 2003-02-19 |
AU1255600A (en) | 2000-06-13 |
US6121253A (en) | 2000-09-19 |
JP2002530411A (ja) | 2002-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69905488T2 (de) | Prostaglandin-konjugate zur behandlung von knochenkrankheiten | |
SE9901272D0 (sv) | New improved formulation | |
BR0016058A (pt) | Compostos de fosfonato | |
DE69331326T2 (de) | Prostaglandin-analoga zur behandlung von osteoporose | |
NZ294933A (en) | Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents | |
DE60113537D1 (de) | Methode zur verabreichung von biphosphonaten | |
PL1663185T3 (pl) | Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego | |
ATE232873T1 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
ATE293450T1 (de) | Verwendung von biphosphonsäuren zur behandlung von angiogenese | |
DE69906345D1 (de) | Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten | |
TR199902703T2 (xx) | Proteaz inhibit�rleri. | |
ATE357921T1 (de) | Alendronate zur behandlung von osteoporose | |
ATE277026T1 (de) | Naphthylverbindungen, zusammensetzungen und verfahren | |
ATE284221T1 (de) | Pflanzenextrakte zur behandlung einer gesteigerten knochenresorption | |
DE60212621D1 (de) | Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis | |
ATE263566T1 (de) | Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom | |
DE69921346D1 (de) | Pflanzenextrakte zur behandlung einer gesteigerten knochenresorption | |
ATE245637T1 (de) | Benzothiophenverbindungen, zubereitungen und verfahren | |
DE69934113D1 (de) | Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen | |
DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
ATE272651T1 (de) | Verbindungen mit wachstumshormon-freisetzender eigenschaft | |
FR2783518B1 (fr) | Inhibiteurs de lta4 hydrolase | |
ATE224735T1 (de) | Mittel zur spezifischen hemmung osteoklastärer knochenresorption | |
DE59509229D1 (de) | Verwendung von phosphorderivaten von alkaloiden zur behandlung von endokrinopathien | |
DE69711528T2 (de) | Naphthofluorenverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |